Shionogi & Co., Ltd. (OTCMKTS:SGIOY) Sees Large Drop in Short Interest

Shionogi & Co., Ltd. (OTCMKTS:SGIOYGet Free Report) saw a large decrease in short interest in May. As of May 15th, there was short interest totalling 2,100 shares, a decrease of 87.6% from the April 30th total of 17,000 shares. Based on an average daily volume of 79,600 shares, the short-interest ratio is currently 0.0 days.

Shionogi & Co., Ltd. Trading Down 0.6 %

Shares of OTCMKTS:SGIOY traded down $0.07 on Wednesday, reaching $10.97. 219,818 shares of the company traded hands, compared to its average volume of 66,581. The stock has a market capitalization of $13.01 billion, a P/E ratio of 11.31, a price-to-earnings-growth ratio of 1.69 and a beta of 0.26. The business’s 50-day simple moving average is $11.90 and its 200 day simple moving average is $12.06. The company has a current ratio of 5.47, a quick ratio of 5.03 and a debt-to-equity ratio of 0.01. Shionogi & Co., Ltd. has a 52 week low of $10.10 and a 52 week high of $13.67.

Shionogi & Co., Ltd. (OTCMKTS:SGIOYGet Free Report) last posted its quarterly earnings results on Monday, May 13th. The company reported $0.21 earnings per share (EPS) for the quarter. Shionogi & Co., Ltd. had a return on equity of 13.08% and a net margin of 37.29%. The business had revenue of $662.08 million for the quarter. As a group, equities analysts anticipate that Shionogi & Co., Ltd. will post 0.82 EPS for the current fiscal year.

Shionogi & Co., Ltd. Company Profile

(Get Free Report)

Shionogi & Co, Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Cabenuva and Apretude an anti-HIV and HIV prophylactic drug; Xocova an oral COVID-19 treatment drug; Finibax a carbapenem antibiotic; Xofluza, an influenza antiviral drug; and Tivicay, an anti-HIV drug.

Featured Articles

Receive News & Ratings for Shionogi & Co. Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shionogi & Co. Ltd. and related companies with's FREE daily email newsletter.